Skip to main content
GNPX
NASDAQ Life Sciences

Genprex Seeks Shareholder Approval for Another Reverse Stock Split and Significant Equity Plan Increase Amidst Delisting Risk

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$1.3
Mkt Cap
$11.758M
52W Low
$1.15
52W High
$55
Market data snapshot near publication time

Summary

Genprex is asking shareholders to approve another reverse stock split (1:5 to 1:50) to maintain its Nasdaq listing, despite having completed two recent splits, and a 20% increase in its equity incentive plan, highlighting significant financial and compliance pressures.


Key Events

  • Authorization for Another Reverse Stock Split

    Shareholders are asked to approve an amendment to the company's charter to effect a reverse stock split at a ratio between 1:5 and 1:50, at the Board's discretion, until December 31, 2027. This is primarily aimed at maintaining compliance with Nasdaq's $1.00 minimum bid price requirement.

  • History of Reverse Stock Splits and Delisting Risk

    The company previously implemented a 1:40 reverse stock split in February 2024 and a 1:50 reverse stock split in October 2025. The filing highlights that under amended Nasdaq rules, if another reverse split is implemented and the stock price falls below $1.00 within one year, the company will face immediate delisting without a compliance period, indicating a heightened risk.

  • Significant Increase in Equity Incentive Plan

    The Board recommends increasing the shares authorized for issuance under the 2018 Equity Incentive Plan by an additional 1,850,000 shares. This represents a potential dilution of approximately 20.1% based on the 9,205,437 shares outstanding as of April 15, 2026.


Analysis

Genprex, Inc. is seeking shareholder approval for two critical proposals at its upcoming annual meeting: a reverse stock split and a substantial increase in its equity incentive plan. The proposed reverse stock split, with a ratio ranging from 1:5 to 1:50, is intended to help the company maintain its Nasdaq listing, which requires a minimum bid price of $1.00. This is particularly concerning as the company has already implemented two reverse stock splits (1:40 in February 2024 and 1:50 in October 2025) in a short period. The filing explicitly warns that under amended Nasdaq rules, if another reverse split is implemented and the stock price subsequently falls below $1.00 within a year, the company will face immediate delisting without a compliance period. This indicates a precarious position regarding its listing status. Additionally, the company is requesting to increase the shares authorized for its 2018 Equity Incentive Plan by an additional 1,850,000 shares, representing a potential dilution of over 20% based on current outstanding shares. This significant potential dilution, coupled with the ongoing struggle to maintain Nasdaq compliance, signals considerable financial and operational challenges for the company.

At the time of this filing, GNPX was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.8M. The 52-week trading range was $1.15 to $55.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GNPX - Latest Insights

GNPX
Jun 12, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.645201
Real-time Price: $0.6313 info
Change: -$0.013901 (-2%) info
Market Cap: $6.777M info
GNPX
Jun 12, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.6438
Real-time Price: $0.6313 info
Change: -$0.0125 (-2%) info
Market Cap: $6.777M info
GNPX
Jun 05, 2026, 5:01 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $0.650
Real-time Price: $0.6313 info
Change: -$0.0187 (-3%) info
Market Cap: $6.777M info
GNPX
May 26, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.823511
Real-time Price: $0.6313 info
Change: -$0.192211 (-23%) info
Market Cap: $6.777M info
GNPX
May 13, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.8511
Real-time Price: $0.6313 info
Change: -$0.2198 (-26%) info
Market Cap: $6.777M info
GNPX
Apr 30, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.9096
Real-time Price: $0.6313 info
Change: -$0.2783 (-31%) info
Market Cap: $6.777M info
GNPX
Apr 30, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.920
Real-time Price: $0.6313 info
Change: -$0.2887 (-31%) info
Market Cap: $6.777M info
GNPX
Apr 29, 2026, 4:47 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.8801
Real-time Price: $0.6313 info
Change: -$0.2488 (-28%) info
Market Cap: $6.777M info
GNPX
Apr 28, 2026, 7:07 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.938
Real-time Price: $0.6313 info
Change: -$0.3067 (-33%) info
Market Cap: $6.777M info
GNPX
Apr 21, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.22
Real-time Price: $0.6313 info
Change: -$0.5887 (-48%) info
Market Cap: $6.777M info